Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275352 | 0.88 | MGAM (0.59) | CYP3A4CYP1B1HDAC8HDAC6HDAC1 | |
| SCHEMBL10275051 | 0.87 | KMT2A (0.58) | CYP3A4CYP1B1HDAC8HDAC6HDAC1 | |
| SCHEMBL10275506 | 0.86 | MAPT (0.59) | CYP3A4CYP1B1HDAC8HDAC6HDAC1 | |
| SCHEMBL15284971 | 0.84 | CYP1A1 (0.59) | CYP3A4CYP1B1HDAC8HDAC6HDAC1 | |
| SCHEMBL10275214 | 0.84 | CYP3A4 (0.59) | CYP3A4CYP1B1CNR2MGAMKMT2A | |
| SCHEMBL5090120 | 0.82 | ALDH1A1 (0.50) | CYP3A4CYP1B1MAPTALDH1A1KMT2A | |
| SCHEMBL27784008 | 0.81 | MAPT (0.56) | CYP3A4HDAC8HDAC6HDAC1HDAC2 | |
| SCHEMBL10275150 | 0.80 | CNR2 (0.49) | HDAC8HDAC6HDAC1HDAC2HDAC3 | |
| SCHEMBL10275177 | 0.78 | CYP1A1 (0.62) | CYP3A4CYP1B1MAPTKMT2ARAB9A | |
| SCHEMBL1385625 | 0.77 | ALDH1A1 (0.47) | HDAC8HDAC6HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | claimed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-116615241-A | Methods and compositions for diabetes treatment and beta cell regeneration | 加利福尼亚大学董事会 | 2023-08-18 | — | — | CN | disclosed |
| EP-4200016-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040161-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2017208174-A2 | METHODS OF TREATING DISEASE WITH PFKFB3 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | WO | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1748987-A2 | 2-PROPENE-1-ONES AS HSP 70 INDUCERS | Torrent Pharmaceuticals Ltd (IN) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005097746-A2 | 2-PROPENE-1-ONES AS HSP 70 INDUCERS | TORRENT PHARMACEUTICALS LTD (IN) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | CYP3A4 4440/4885CYP1B1 4552/4885HDAC8 809/4885 |
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | HSPB1, HSF1, HSPE1 | CYP3A4 1868/4885CYP1B1 620/4885HDAC8 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.